• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by CM Life Sciences, Inc.

    7/9/21 11:55:18 AM ET
    $CMLF
    Business Services
    Finance
    Get the next $CMLF alert in real time by email
    SC 13G 1 tm2121771d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549 

     

     

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934 

    (Amendment No.  )*

     

    CM Life Sciences, Inc.

     

    (Name of Issuer)

     

    Common stock

     

    (Title of Class of Securities)

     

    18978W109

     

    (CUSIP Number)

     

    June 30, 2021

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x  Rule 13d-1(b)

     

    ¨  Rule 13d-1(c)

     

    ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    CUSIP No. 18978W109 13G Page 2 of 5 Pages 

     

    1. NAMES OF REPORTING PERSONS    
    ARK Investment Management LLC    
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP    
    (a) ¨    
    (b) ¨    
    3. SEC USE ONLY    
         
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION    
    Delaware, United States    
       

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER    
     4,581,277    
       
    6. SHARED VOTING POWER    
       0       
       
    7. SOLE DISPOSITIVE POWER    
     4,581,277    
       
    8. SHARED DISPOSITIVE POWER    
    0    
       

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON    
     4,581,277    
       
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES    
    ¨    
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)    
    10.35%    
       
    12. TYPE OF REPORTING PERSON    
    IA    
       

     

     

     

     

    CUSIP No. 18978W109 13G Page 3 of 5 Pages 

     

    Item 1(a) Name of issuer:

     

    CM Life Sciences, Inc.

     

    Item 1(b) Address of issuer's principal executive offices:

     

    c/o Corvex Management LP

    667 Madison Avenue

    New York, NY 10020

     

    Item 2(a) Name of person filing:

     

    ARK Investment Management LLC

     

    Item 2(b) Address or principal business office or, if none, residence:

     

    ARK Investment Management LLC

    3 East 28th Street, 7th Floor 

    New York, NY 10016

     

    Item 2(c) Citizenship:

     

    Delaware, United States

     

    Item 2(d) Title of class of securities:

     

    Common stock

     

    Item 2(e) CUSIP No.:

     

    18978W109

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f)  ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

     

     

    CUSIP No. 18978W109 13G Page 4 of 5 Pages 

     

    (i)  ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)  ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4. Ownership

     

    (a)          Amount beneficially owned:

     

    4,581,277

     

    (b)          Percent of class:

     

    10.35%

     

    (c)          Number of shares as to which such person has:

     

    (i)  Sole power to vote or to direct the vote:  4,581,277

     

    (ii) Shared power to vote or to direct the vote:  0

     

    (iii) Sole power to dispose or to direct the disposition of:  4,581,277

     

    (iv) Shared power to dispose or to direct the disposition of:  0

     

    Item 5. Ownership of 5 Percent or Less of a Class.

     

    Not applicable.

     

    Item 6.Ownership of More than 5 Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

     

     

     

    CUSIP No. 18978W109 13G Page 5 of 5 Pages 

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    The reporting persons agree that this statement is filed on behalf of each of them.

     

    Dated:    July 9, 2021

     

     

    ARK Investment Management LLC

         
      By: /s/ Kellen Carter
        Name:  Kellen Carter
        Title:    Chief Compliance Officer
         

     

     

     

     

    Get the next $CMLF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CMLF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CMLF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Sherman Rachel E.

      4 - Sema4 Holdings Corp. (0001818331) (Issuer)

      10/19/21 7:31:01 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form 4 filed by Turner Nat

      4 - Sema4 Holdings Corp. (0001818331) (Issuer)

      10/19/21 7:29:25 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form 4 filed by Pellini Michael J

      4 - Sema4 Holdings Corp. (0001818331) (Issuer)

      10/19/21 7:27:37 PM ET
      $CMLF
      Business Services
      Finance

    $CMLF
    Financials

    Live finance-specific insights

    See more
    • Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

      37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period last year Reiterating full year 2022 total revenue guidance of $215-225 million Sema4 to host conference call today at 4:30 p.m. ET STAMFORD, Conn., March 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), an AI-driven genomic and clinical data intelligence platform company, today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on key strategic and ope

      3/14/22 4:05:00 PM ET
      $CMLF
      $SMFR
      Business Services
      Finance
      Retail: Computer Software & Peripheral Equipment
      Technology

    $CMLF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by CM Life Sciences, Inc.

      SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)

      10/13/21 2:31:34 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form SC 13D filed by CM Life Sciences, Inc.

      SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)

      8/30/21 4:45:58 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form SC 13D filed by CM Life Sciences, Inc.

      SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)

      8/2/21 4:59:57 PM ET
      $CMLF
      Business Services
      Finance

    $CMLF
    Leadership Updates

    Live Leadership Updates

    See more
    • Sema4 Appoints Andrew Kasarskis, Health Data Expert and Precision Medicine Scientist, as Chief Data Officer

      Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the appointment of Andrew Kasarskis, PhD, to the newly established role of Chief Data Officer (CDO). Dr. Kasarskis brings more than 20 years of leadership and broad experience in industry and academia that includes a strong focus on digital analytics and genomics and internationally recognized research in the life sciences. At Sema4, he will be responsible for establishing additional structures and processes to further optimize the company's health intelligence platform and orchestrating data use and data science to support research, development, and innov

      6/17/21 7:00:00 AM ET
      $CMLF
      Business Services
      Finance

    $CMLF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

      37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period last year Reiterating full year 2022 total revenue guidance of $215-225 million Sema4 to host conference call today at 4:30 p.m. ET STAMFORD, Conn., March 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), an AI-driven genomic and clinical data intelligence platform company, today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on key strategic and ope

      3/14/22 4:05:00 PM ET
      $CMLF
      $SMFR
      Business Services
      Finance
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company

      Sema4 Holdings Corp ("Sema4") to debut on Nasdaq as a publicly traded company dedicated to transforming healthcare by applying artificial intelligence and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human healthBusiness combination expected to result in ~$500 million in cash proceeds to Sema4 to accelerate organic and inorganic growthCombined company to trade on Nasdaq under ticker "SMFR" STAMFORD, Conn., July 22, 2021 (GLOBE NEWSWIRE) -- Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the completion of its business combination with CM Life

      7/22/21 9:15:41 AM ET
      $TWST
      $MGTA
      $CMLF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Business Services
    • Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of Directors

      Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the appointment of renowned executive Jason Ryan to its Board of Directors. Mr. Ryan will begin serving on Sema4's Board of Directors upon his official appointment after Sema4 closes its previously announced business combination with CM Life Sciences (NASDAQ:CMLF), a special purpose acquisition company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005228/en/Jason Ryan (Photo: Business Wire) Mr. Ryan most recently served as Chief Operating and Financial Officer of Magenta Therapeutics (NA

      7/7/21 7:00:00 AM ET
      $TWST
      $CMLF
      $MGTA
      $OMIC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Business Services
      Finance

    $CMLF
    SEC Filings

    See more
    • SEC Form 424B3 filed by CM Life Sciences, Inc.

      424B3 - Sema4 Holdings Corp. (0001818331) (Filer)

      10/14/21 9:58:15 PM ET
      $CMLF
      Business Services
      Finance
    • CM Life Sciences, Inc. filed SEC Form 8-K: Leadership Update

      8-K - Sema4 Holdings Corp. (0001818331) (Filer)

      10/14/21 5:23:09 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form S-8 filed by CM Life Sciences, Inc.

      S-8 - Sema4 Holdings Corp. (0001818331) (Filer)

      9/27/21 4:46:23 PM ET
      $CMLF
      Business Services
      Finance